Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous versus oral Aspirin in acute coronary syndrome for rapid thromboxane inhibition
2007-005163-94Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in acute coronary syndrome (ACS) (3 arms), sponsored by Bayer. Primary endpoint: TXB2 concentration at 5 minutes after study drug administration. Started Jul 2009; status: completed.
02
Drugs
aspirin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2007-005163-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005163-94.